Agnieszka Konska
Warsaw, MZ, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.
Journal: The Lancet. Haematology
Published: November 21, 2025
Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.
Journal: British journal of haematology
Published: October 09, 2025
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
Journal: Polish archives of internal medicine
Published: May 15, 2024
Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group.
Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University
Published: January 05, 2023
Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma.
Journal: European journal of haematology
Published: July 14, 2019
Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumab‑associated anaphylaxis.
Journal: Polish archives of internal medicine
Published: September 04, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026